Gili Kenet

CONSULTANT PAEDIATRIC HAEMATOLOGIST
National Hemophilia Center Sheba Medical center, Tel Hashomer & Amalia Biron Research Institute of Thrombosis & Hemostasis, Tel Aviv University, Israel,
Tel Aviv, Tel Aviv, Israel

Presentation(s):

• OC 02.4 - Long-Term Follow-Up of Participants in the Phase I/II Trial of Dirloctocogene Samoparvovec (SPK-8011): Durable FVIII Expression and Clinically Meaningful Reduction of Bleeding

  Saturday, June 22, 2024
  13:45 – 14:00 ICT

• OC 30.2 - Efficacy and safety of valoctocogene roxaparvovec 4 years after gene transfer in GENEr8-1

  Monday, June 24, 2024
  09:45 – 10:00 ICT

• OC 30.3 - Health-related quality-of-life outcomes 4 years after treatment with valoctocogene roxaparvovec

  Monday, June 24, 2024
  10:00 – 10:15 ICT

• OC 31.2 - Hydroxychloroquine Treatment for Improving Pregnancy Outcomes in Patients with Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis

  Monday, June 24, 2024
  09:45 – 10:00 ICT

• PB0638 - Early initiation of prophylaxis does not necessarily prevent Intracranial hemorrhage in infants with severe haemophilia A – a single center experience

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0511 - Impact of Emicizumab prophylaxis on Healthcare Utilization among Hemophilia A patients

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0634 - The MAPTO survey, Mapping Approaches to Tolerance in PUP/MTP treatment around the world in the non-replacement era

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB1184 - A survey of clinical practice of laboratory monitoring and management of bleeding in children on emicizumab prophylaxis in the PedNet centers

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• OC 71.2 - Intracranial hemorrhage before the initiation of prophylaxis in early age in hemophilia A – data from the PedNet registry

  Wednesday, June 26, 2024
  10:30 – 10:45 ICT